US · AARD
Aardvark Therapeutics, Inc. Common Stock
Programmatic access: InvestorsCraft Valuation API · catalog
Price · as of 2026-09-04
$5.38
Market cap 164.57M
Price history
| Week | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 10, 2025 – Feb 14, 2025 | $15.18 | $15.18 | $11.55 | $13.30 | 0 |
| Feb 17, 2025 – Feb 21, 2025 | $13.39 | $19.58 | $12.58 | $13.74 | 0 |
| Feb 24, 2025 – Feb 28, 2025 | $14.22 | $15.80 | $12.21 | $12.73 | 0 |
| Mar 3, 2025 – Mar 7, 2025 | $12.94 | $13.60 | $9.21 | $10.13 | 0 |
| Mar 10, 2025 – Mar 14, 2025 | $10.90 | $11.78 | $9.40 | $10.01 | 0 |
| Mar 17, 2025 – Mar 21, 2025 | $9.80 | $10.51 | $8.60 | $9.91 | 0 |
| Mar 24, 2025 – Mar 28, 2025 | $9.91 | $10.38 | $7.74 | $7.74 | 0 |
| Mar 31, 2025 – Apr 4, 2025 | $7.46 | $9.70 | $6.79 | $8.16 | 0 |
| Apr 7, 2025 – Apr 11, 2025 | $8.27 | $8.30 | $4.88 | $7.14 | 0 |
| Apr 14, 2025 – Apr 17, 2025 | $7.12 | $7.99 | $6.89 | $7.00 | 0 |
| Apr 21, 2025 – Apr 25, 2025 | $6.86 | $8.55 | $6.75 | $7.93 | 0 |
| Apr 28, 2025 – May 2, 2025 | $8.01 | $13.56 | $8.01 | $12.86 | 0 |
| May 5, 2025 – May 9, 2025 | $13.25 | $13.25 | $10.00 | $10.42 | 0 |
| May 12, 2025 – May 16, 2025 | $10.40 | $11.38 | $8.50 | $9.89 | 0 |
| May 19, 2025 – May 23, 2025 | $10.02 | $11.50 | $9.67 | $10.50 | 0 |
| May 26, 2025 – May 30, 2025 | $10.48 | $10.93 | $9.76 | $10.44 | 0 |
| Jun 2, 2025 – Jun 6, 2025 | $10.72 | $12.22 | $10.72 | $11.81 | 0 |
| Jun 9, 2025 – Jun 13, 2025 | $12.19 | $12.53 | $10.50 | $10.74 | 0 |
| Jun 16, 2025 – Jun 20, 2025 | $10.96 | $12.18 | $10.29 | $11.13 | 0 |
| Jun 23, 2025 – Jun 27, 2025 | $10.54 | $16.32 | $10.54 | $13.39 | 0 |
| Jun 30, 2025 – Jul 3, 2025 | $14.10 | $14.14 | $12.82 | $13.92 | 0 |
| Jul 7, 2025 – Jul 11, 2025 | $14.11 | $14.54 | $12.11 | $12.17 | 0 |
| Jul 14, 2025 – Jul 18, 2025 | $12.01 | $12.58 | $11.09 | $11.62 | 0 |
| Jul 21, 2025 – Jul 25, 2025 | $11.61 | $15.17 | $11.51 | $14.70 | 0 |
| Jul 28, 2025 – Aug 1, 2025 | $14.72 | $15.01 | $11.50 | $12.13 | 0 |
| Aug 4, 2025 – Aug 8, 2025 | $12.47 | $13.63 | $11.50 | $11.99 | 0 |
| Aug 11, 2025 – Aug 15, 2025 | $12.41 | $12.41 | $9.75 | $10.78 | 0 |
| Aug 18, 2025 – Aug 22, 2025 | $10.85 | $10.85 | $9.32 | $9.77 | 0 |
| Aug 25, 2025 – Aug 29, 2025 | $9.80 | $9.80 | $8.20 | $8.30 | 0 |
| Sep 1, 2025 – Sep 5, 2025 | $8.45 | $9.09 | $8.03 | $8.60 | 0 |
| Sep 8, 2025 – Sep 12, 2025 | $8.68 | $8.70 | $7.50 | $8.59 | 0 |
| Sep 15, 2025 – Sep 19, 2025 | $9.01 | $11.82 | $8.70 | $10.89 | 0 |
| Sep 22, 2025 – Sep 26, 2025 | $10.95 | $13.50 | $10.86 | $13.23 | 0 |
| Sep 29, 2025 – Oct 3, 2025 | $13.60 | $16.35 | $12.71 | $16.08 | 0 |
| Oct 6, 2025 – Oct 10, 2025 | $16.49 | $17.94 | $15.71 | $16.26 | 0 |
| Oct 13, 2025 – Oct 17, 2025 | $16.31 | $16.39 | $12.32 | $12.81 | 0 |
| Oct 20, 2025 – Oct 24, 2025 | $12.77 | $12.86 | $10.65 | $10.70 | 0 |
| Oct 27, 2025 – Oct 31, 2025 | $11.00 | $12.16 | $10.23 | $10.69 | 0 |
| Nov 3, 2025 – Nov 7, 2025 | $10.66 | $10.94 | $9.34 | $10.14 | 0 |
| Nov 10, 2025 – Nov 14, 2025 | $10.21 | $11.51 | $9.75 | $9.92 | 0 |
| Nov 17, 2025 – Nov 21, 2025 | $9.97 | $11.23 | $8.82 | $9.37 | 0 |
| Nov 24, 2025 – Nov 28, 2025 | $9.53 | $10.44 | $9.28 | $9.98 | 0 |
| Dec 1, 2025 – Dec 5, 2025 | $9.95 | $13.77 | $9.18 | $13.56 | 0 |
| Dec 8, 2025 – Dec 12, 2025 | $13.80 | $16.00 | $12.54 | $14.43 | 0 |
| Dec 15, 2025 – Dec 19, 2025 | $15.64 | $15.75 | $12.90 | $13.77 | 0 |
| Dec 22, 2025 – Dec 26, 2025 | $13.81 | $15.33 | $13.58 | $13.65 | 0 |
| Dec 29, 2025 – Jan 2, 2026 | $13.90 | $14.34 | $12.50 | $13.19 | 0 |
| Jan 5, 2026 – Jan 9, 2026 | $13.48 | $15.00 | $12.78 | $14.27 | 0 |
| Jan 12, 2026 – Jan 16, 2026 | $14.27 | $16.00 | $14.25 | $15.37 | 0 |
| Jan 19, 2026 – Jan 23, 2026 | $15.00 | $16.60 | $14.80 | $15.01 | 0 |
| Jan 26, 2026 – Jan 30, 2026 | $14.94 | $15.37 | $12.43 | $12.99 | 0 |
| Feb 2, 2026 – Feb 6, 2026 | $12.84 | $13.83 | $11.14 | $12.65 | 0 |
| Feb 9, 2026 – Feb 13, 2026 | $12.65 | $13.58 | $12.00 | $12.10 | 0 |
| Feb 16, 2026 – Feb 20, 2026 | $12.09 | $13.00 | $12.00 | $12.32 | 0 |
| Feb 23, 2026 – Feb 27, 2026 | $12.42 | $12.90 | $12.06 | $12.49 | 0 |
| Mar 2, 2026 – Mar 6, 2026 | $5.98 | $6.00 | $4.74 | $5.85 | 0 |
| Mar 9, 2026 – Mar 13, 2026 | $5.70 | $6.50 | $4.83 | $5.09 | 0 |
| Mar 16, 2026 – Mar 20, 2026 | $5.07 | $5.49 | $4.06 | $4.07 | 0 |
| Mar 23, 2026 – Mar 27, 2026 | $4.06 | $4.17 | $3.35 | $3.55 | 0 |
| Mar 30, 2026 – Apr 2, 2026 | $3.58 | $4.30 | $3.49 | $4.30 | 0 |
| Apr 6, 2026 – Apr 10, 2026 | $4.30 | $4.39 | $3.80 | $3.94 | 0 |
| Apr 13, 2026 – Apr 17, 2026 | $3.88 | $5.37 | $3.88 | $5.23 | 0 |
| Apr 20, 2026 – Apr 24, 2026 | $5.16 | $5.83 | $5.10 | $5.39 | 0 |
| Apr 27, 2026 – May 1, 2026 | $5.40 | $5.70 | $4.88 | $5.46 | 0 |
| May 4, 2026 – May 8, 2026 | $5.38 | $5.93 | $5.24 | $5.44 | 0 |
| May 11, 2026 – May 15, 2026 | $5.45 | $6.79 | $4.10 | $4.57 | 0 |
| May 18, 2026 – May 22, 2026 | $4.49 | $5.11 | $4.05 | $4.54 | 0 |
| May 25, 2026 – May 29, 2026 | $4.58 | $4.67 | $3.90 | $4.11 | 0 |
| Jun 1, 2026 – Jun 5, 2026 | $3.99 | $4.12 | $3.66 | $3.68 | 0 |
| Jun 8, 2026 – Jun 12, 2026 | $3.73 | $3.99 | $3.40 | $3.90 | 0 |
| Jun 15, 2026 – Jun 18, 2026 | $3.90 | $4.10 | $3.65 | $3.93 | 0 |
| Jun 22, 2026 – Jun 26, 2026 | $3.96 | $5.53 | $3.91 | $4.79 | 0 |
| Jun 29, 2026 – Jul 2, 2026 | $4.78 | $5.99 | $4.70 | $5.70 | 0 |
| Jul 6, 2026 – Jul 10, 2026 | $5.59 | $7.92 | $4.66 | $7.60 | 0 |
| Jul 13, 2026 – Jul 17, 2026 | $7.35 | $7.92 | $5.73 | $5.86 | 0 |
| Jul 20, 2026 – Jul 24, 2026 | $5.87 | $6.90 | $5.35 | $6.32 | 0 |
| Jul 27, 2026 – Jul 31, 2026 | $6.40 | $6.80 | $5.30 | $6.60 | 0 |
| Aug 3, 2026 – Aug 7, 2026 | $6.65 | $8.12 | $6.64 | $7.90 | 0 |
| Aug 10, 2026 – Aug 14, 2026 | $7.76 | $7.76 | $6.18 | $6.54 | 0 |
| Aug 17, 2026 – Aug 21, 2026 | $6.54 | $7.51 | $5.76 | $6.82 | 0 |
| Aug 24, 2026 – Aug 28, 2026 | $6.75 | $7.31 | $5.62 | $5.79 | 0 |
| Aug 31, 2026 – Sep 4, 2026 | $5.70 | $6.25 | $5.15 | $5.38 | 0 |
Valuation
| Metric | Value | Upside |
|---|---|---|
| IC Value | — | — |
| P/E | -1.93 | |
| P/B | 1.04 | |
| P/S | — | |
| EV/EBITDA | -0.03 | |
| PEG | -1.08 | |
| P/TBV | 1.04 |
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | IC | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | |||||
| 2024 | $10.13 | ||||
| 2025 | $5.09 |
Historic valuation ratios
Pick a category, then toggle metrics to compare.
Line items
Line items
Line items
About Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
- CEO
- Tien-Li Lee
- Employees
- 40
- Beta
- 3.81
Scroll horizontally for additional metrics. Ticker column stays fixed.
| Basic Info | IC Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | Value | Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AARD | Aardvark Therapeutics, In… | $7.90 | 164.57M | — | — | -1.93 | 1.04 | — | -0.03 | -1.08 | 1.04 | 0.00% | 0.00% | 0.00% | -221.55% | 96.15% | -59.16% | 0.00 | — | 10.61 | 10.43 | 0.81 | 177.89% | — | 198.24% | -48.87% | -5.14 | 83.18% | 0.00% | 0.00% | 0.00% | -0.02 | -0.03 | — | 4.20 |
| ASMB | Assembly Biosciences, Inc… | $26.54 | 421.72M | $28.67 | +8% | -51.49 | 1.52 | 4.36 | -11.64 | — | 1.52 | 99.82% | -16.76% | -8.47% | -5.10% | 21.19% | -3.25% | 0.01 | — | 5.22 | 5.11 | 9.31 | -91.78% | 153.52% | -19.52% | -13.06% | -0.84 | 71.98% | 0.00% | 0.00% | 6.52% | -5.76 | -1.70 | 0.97 | 0.28 |
| AVTX | Avalo Therapeutics, Inc. | $18.84 | 212.78M | $11.15 | -41% | -2.71 | 2.55 | 3589.77 | -1.49 | -3.42 | 2.92 | 100.00% | -123601.69% | -132642.37% | -72.43% | 1056.42% | -58.58% | 0.03 | — | 8.14 | 7.60 | 0.17 | 79.14% | -86.62% | 4.90% | -24.30% | -3.98 | 745.44% | 0.00% | 0.00% | 0.00% | -1.59 | -2.25 | 1964.19 | -2.70 |
| CRBU | Caribou Biosciences, Inc. | $1.61 | 159.68M | $11.47 | +612% | -1.19 | 1.44 | 15.73 | -0.44 | — | 1.44 | 67.34% | -1220.49% | -1327.40% | -78.97% | -339.38% | -60.62% | 0.22 | — | 5.71 | 5.60 | -0.10 | -3.64% | 11.66% | -22.36% | -63.99% | -4.37 | -281.01% | 0.00% | 0.00% | 0.00% | -0.47 | -0.56 | 5.69 | -4.46 |
| ENTA | Enanta Pharmaceuticals, I… | $13.22 | 384.42M | $26.62 | +101% | -3.80 | 4.81 | 4.77 | -4.57 | — | 4.81 | 92.98% | -130.65% | -125.36% | -84.63% | -91.13% | -24.91% | 3.11 | -11.11 | 4.21 | 4.03 | -2.38 | -29.93% | -3.42% | -66.74% | -10.33% | -0.40 | -35.04% | 0.00% | 0.00% | 6.44% | -3.79 | -10.06 | 4.96 | -1.26 |
| EPRX | Eupraxia Pharmaceuticals … | $6.48 | 216.95M | — | — | -7.50 | 3.58 | — | -4.01 | -21.11 | 3.58 | 0.00% | 0.00% | 0.00% | -67.94% | -5345.43% | -64.78% | 0.00 | — | 15.12 | 14.43 | 1.51 | 35.53% | — | -1.57% | -10.07% | -5.16 | -2951.37% | 0.00% | 0.00% | 16.11% | -3.98 | -7.21 | — | 27.23 |
| FHTX | Foghorn Therapeutics Inc. | $4.88 | 286.52M | $13.56 | +178% | -4.15 | -2.84 | 9.98 | -2.69 | — | -2.84 | 89.22% | -265.64% | -240.33% | 96.45% | 34.34% | -30.82% | -0.38 | — | 2.73 | 2.66 | 0.56 | -25.32% | 36.75% | -14.97% | -27.92% | -1.44 | 36.03% | 0.00% | 0.00% | 6.90% | -2.33 | -2.22 | 6.18 | -4.45 |
| NAUT | Nautilus Biotechnolgy, In… | $0.93 | 118.35M | — | — | -4.99 | 1.87 | — | -4.20 | — | 1.87 | 0.00% | 0.00% | 0.00% | -32.27% | -69.30% | -27.20% | 0.19 | — | 13.33 | 13.00 | -0.34 | -16.07% | — | -15.17% | -17.67% | -6.38 | -53.89% | 0.00% | 0.00% | 0.00% | -3.30 | -4.25 | — | 2.20 |
| PYXS | Pyxis Oncology, Inc. | $3.13 | 198.3M | — | — | -1.20 | 1.79 | 6.91 | -0.64 | — | 1.79 | 82.77% | -609.18% | -574.55% | -91.43% | -877.36% | -64.03% | 0.35 | — | 3.41 | 3.20 | -0.04 | -3.03% | -14.17% | 9.67% | -66.36% | -3.01 | -660.06% | 0.00% | 0.00% | 0.00% | -0.56 | -0.75 | 3.43 | -7.50 |
| TNYA | Tenaya Therapeutics, Inc. | $0.78 | 170.28M | — | — | -1.44 | 1.06 | — | -0.49 | — | 1.06 | 0.00% | 0.00% | 0.00% | -83.84% | -237.59% | -67.90% | 0.09 | — | 6.84 | 6.51 | 1.09 | -54.96% | — | -24.74% | -52.85% | -4.42 | -175.35% | 0.00% | 0.00% | 75.96% | -0.44 | -0.59 | — | -3.82 |
| ZURA | Zura Bio Limited | $5.64 | 535.79M | — | — | -8.46 | 5.72 | — | -6.87 | -11.04 | 5.72 | 0.00% | 0.00% | 0.00% | -55.28% | 400.76% | -46.78% | 0.00 | — | 9.05 | 8.82 | 1.59 | 76.67% | — | 130.64% | -11.18% | -5.22 | 345.80% | 0.00% | 0.00% | 0.00% | -6.27 | -7.26 | — | 24.20 |
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $5.38) − 1 = — (IC, example).